Therapeutic Immunomodulation in Gastric Cancer.

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Gastric carcinoma (GC) is a leading cause of cancer death globally, with complex symptoms hindering early detection.
• Advanced or metastatic GC treatment has seen significant progress with immune checkpoint inhibition.
• Immunotherapy presents an effective, tolerable alternative to traditional therapies for GC.

Purpose of the Study:

• To review recent advancements in immunotherapy for advanced gastric cancer.
• To examine current clinical applications of immunotherapies for GC.
• To address challenges and explore future strategies in GC immunotherapy.

Main Methods:

• Review of current literature on advanced gastric cancer immunotherapies.
• Analysis of immune checkpoint inhibitors, cancer vaccines, VEGF-A inhibitors, and CAR T-cell therapy.
• Discussion of clinical trial data and therapeutic outcomes.

Main Results:

• Immunotherapy demonstrates significant effectiveness and tolerable toxicity in advanced GC.
• Various immunotherapeutic strategies are under investigation in clinical trials.
• Immune checkpoint inhibitors are a new standard for advanced GC treatment.

Conclusions:

• Immunotherapy is a rapidly advancing and effective treatment modality for advanced gastric cancer.
• Addressing current challenges is crucial for optimizing immunotherapy outcomes.
• Future strategies hold promise for overcoming limitations in GC immunotherapy.